Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Nov 10, 2009

Premium

Rosetta Genomics has appointed Kenneth Berlin as president and CEO. Berlin will also serve on the company’s board of directors. Since 2007 Berlin has been worldwide general manager at cellular and molecular cancer diagnostics company Veridex.


Nanosphere said last week that Chief Technology Officer and Vice President of R&D William Cork has resigned from his positions to pursue other opportunities, and that his duties will be reassigned.


WaferGen Biosystems has appointed Christopher Sears to its scientific advisory board. Sears is chief scientific officer at Ambergen, and he has worked as an academic oncologist at Children’s Hospital Boston, The Broad Institute, Harvard Medical School, and Dana Farber Cancer Institute. Sears also has been a scientific adviser to Genzyme Genetics, Myriad Genetics, and Invitrogen.


Sequenom has appointed Paul Maier to begin serving as its interim chief financial officer. He has worked as senior vice president and CFO of Ligand Pharmaceuticals, where he helped build the company from its venture stage through raising more than $1 billion in equity and debt financings. He also worked at ICN Pharmaceuticals for six years in various management and finance positions.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.